

COMPANY OVERVIEW

DelMar Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of new cancer therapies. Our lead product candidate, VAL-083, is a "first-in-class" small molecule chemotherapy that is currently being evaluated in a Phase 2 clinical trial for the treatment of refractory glioblastoma multiforme (GBM), the most common and aggressive form of brain cancer. We are also exploring VAL-083 as a therapy for front-line GBM and solid tumors, including non-small cell lung cancer (NSCLC) and ovarian cancer.

RECENT NEWS

DelMar Pharmaceuticals Announces Accelerated Patient Enrollment of Phase 2 Trial in MGMT-unmethylated Recurrent GBM

Jun 26 2018, 6:00 AM EDT

DelMar Pharmaceuticals Appoints World-Renowned Molecular Biologist Dr. Napoleone Ferrara to Board of Directors

Jun 25 2018, 6:00 AM EDT

DelMar Appoints Saiid Zarrabian to Full-Time President and CEO

May 22 2018, 5:30 AM EDT

STOCK OVERVIEW

Symbol	DMPI
Exchange	Nasdaq
Shares OS	22,012,237
Market Cap	\$13.54M
Last Price	\$0.615
52-Week Range	\$0.608 - \$2.84

INVESTOR RELATIONS

T: (604) 629-5989
ir@delmarpharma.com

MANAGEMENT TEAM

Saiid Zarrabian

President & Chief Executive Officer

Dennis Brown

Chief Scientific Officer

Scott Prail

Chief Financial Officer

DELMAR PHARMACEUTICALS, INC.

Corporate

Suite 720 - 999 West Broadway
Vancouver, BC V5Z 1K5
CA

Clinical Operations

3475 Edison Way
Suite R
Menlo Park, CA 94025
USA

DISCLAIMER

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.